<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268006</url>
  </required_header>
  <id_info>
    <org_study_id>41/12/13</org_study_id>
    <nct_id>NCT02268006</nct_id>
  </id_info>
  <brief_title>IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment</brief_title>
  <acronym>BISER</acronym>
  <official_title>Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <brief_summary>
    <textblock>
      RATIONALE: Using small radiation beamlets of different intensity, IMRT (intensity modulated
      radiation therapy) allows shaping the dose around planning target volume with better sparing
      of normal tissue comparing to 3D conformal radiotherapy. It allows daily delivery of higher
      dose to the tumor with simultaneous integrated boost (SIB), consequently shortening total
      treatment time with potentially better response to treatment. In advanced rectal
      adenocarcinoma excellent response to preoperative radiochemotherapy with complete eradication
      of the primary tumor observed in the histopathological specimen (pathological complete
      response, pCR) correlates with a favorable overall prognosis, so trying to achieve better
      response to preoperative treatment with higher pCR seams feasible.

      PURPOSE:The hypothesis of this study is that in preoperative radiochemotherapy for locally
      advanced rectal adenocarcinoma shortening of the total treatment time with IMRT-SIB to 22
      daily fractions concomitant with capecitabine results in an improved pCR rate from 9%
      (Slovenian trial) to 25%. Secondary objectives are to evaluate pathological down-staging
      rate, histopathological R0 resection rate, sphincter preservation rate, perioperative
      surgical complication rate, local control, disease-free survival (DFS), overall survival
      (OS), late toxicity and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete remission rate (pCR)</measure>
    <time_frame>after the pathological examination of surgical specimens i.e. within 14 days after the operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>According to NCI-CTC (version 4.0): every week for 16 week preoperative, perioperative (0-30 days postoperative), early (30 days - 6 months postoperative), and late (more than 6 months postoperative)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological R0 resection rate</measure>
    <time_frame>after the pathological examination of resected specimens i.e. within 14 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor down-staging rate</measure>
    <time_frame>after the pathological examination of resected specimens i.e. within 14 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sphincter sparing surgical procedure</measure>
    <time_frame>Toxicity/safety: one month after surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional failure rate</measure>
    <time_frame>after 3y and 5y of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>after 3y and 5y of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>after 3y and 5y of the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>before the treatment, after surgery, after1,2,3,4 and 5 years of the operation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IMRT-SIB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT-SIB</intervention_name>
    <arm_group_label>IMRT-SIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>IMRT-SIB</arm_group_label>
    <other_name>(Xeloda, Capecitabine Teva, Ecansya)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>IMRT-SIB</arm_group_label>
    <other_name>Total Mesorectal Exscision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven newly diagnosed primary rectal adenocarcinoma

          -  Locally advanced tumor fulfilling at least one of the following criteria on pelvic
             MRI:

               -  T ≥ 3 or

               -  N ≥ 1

               -  Positive mesorectal fascia (MRF), i.e. tumor or lymph node one mm or less from
                  the mesorectal fascia

               -  Tumor located od 0 - 15 cm above anocutaneous junction or below peritoneum

          -  Age 18 years and more

          -  Signed informed consent

          -  WHO Performance Status 0-2

          -  Patients is considered to be mentally and physically ft for chemotherapy as judged by
             oncologist

          -  Adequate hematological, hepatic and renal function (WBC ≥ 3.0 x 109/L, neu ≥ 1.5 x
             109/L, platelet count ≥ 100 x 109/L, renal clearance ≥ 50 ml/min, bilirubin ≤ 3x
             normal value, aspartate transaminase/alanine transaminase (AST/ALT) ≤ 2,5x normal
             value)

        Exclusion Criteria:

          -  T4 inoperable tumor - extensive growth into cranial part of the sacrum (above S3) or
             the lumbosacral nerve roots

          -  Metastatic or recurrent rectal cancer

          -  Other co-existing malignancy or malignancy within the past 5 years, with the exception
             of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the
             skin

          -  Chronic bowel inflammatory disease

          -  Pregnant or lactating patient

          -  Significant heart disease (uncontrolled hypertension despite of medication (&gt; 150/100
             mmHg), New York Heart Association (NYHA) class III or IV heart disease,unstable angina
             or myocardial infarction within the past 1 year prior the study entry, history of
             significant ventricular arrhythmia requiring treatment)

          -  Inability to consciously sign the consent form due to physical or psychological
             disabilities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasna But-Hadzic, MD</last_name>
      <phone>+38615879503</phone>
      <email>jbut@onko-i.si</email>
    </contact>
    <contact_backup>
      <last_name>Vaneja Velenik, MD,PhD, asist. prof.</last_name>
      <phone>+38615879661</phone>
      <email>vvelenik@onko-i.si</email>
    </contact_backup>
    <investigator>
      <last_name>Jasna But-Hadzic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vaneja Velenik, MD,PhD,asist.prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irena Oblak, MD,PhD,asist.prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franc Anderluh, MD,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajra Secerov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ibrahim Edhemovic, MD,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Brecelj, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrej Vogrin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rihard Hudej</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mirko Omejc, MD,PhD,prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miran Koželj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bojan Krebs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Engels B, De Ridder M, Tournel K, Sermeus A, De Coninck P, Verellen D, Storme GA. Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1476-80. doi: 10.1016/j.ijrobp.2008.10.017. Epub 2009 Feb 21.</citation>
    <PMID>19231097</PMID>
  </reference>
  <reference>
    <citation>Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010 Feb 26;5:17. doi: 10.1186/1748-717X-5-17.</citation>
    <PMID>20187944</PMID>
  </reference>
  <reference>
    <citation>Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, Krishnan S, Das P. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol. 2011 Jun 8;6:63. doi: 10.1186/1748-717X-6-63.</citation>
    <PMID>21651775</PMID>
  </reference>
  <reference>
    <citation>Li JL, Ji JF, Cai Y, Li XF, Li YH, Wu H, Xu B, Dou FY, Li ZY, Bu ZD, Wu AW, Tham IW. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial. Radiother Oncol. 2012 Jan;102(1):4-9. doi: 10.1016/j.radonc.2011.07.030. Epub 2011 Sep 6.</citation>
    <PMID>21903285</PMID>
  </reference>
  <results_reference>
    <citation>Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J. 2006 Oct;47(5):693-700.</citation>
    <PMID>17042060</PMID>
  </results_reference>
  <results_reference>
    <citation>Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol. 2010 Sep 29;5:88. doi: 10.1186/1748-717X-5-88.</citation>
    <PMID>20920276</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>October 15, 2014</last_update_submitted>
  <last_update_submitted_qc>October 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal carcinoma</keyword>
  <keyword>preoperative radiochemotherapy</keyword>
  <keyword>IMRT</keyword>
  <keyword>SIB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

